Motac Neuroscience

Executive Summary

Motac Neuroscience is a UK-based preclinical CRO and drug discovery company specializing in central nervous system disorders, with a particular focus on Parkinson's disease and other movement/cognitive disorders. Founded in 2016, the company provides world-class in vivo and ex vivo proof-of-concept and efficacy studies to pharmaceutical and biotech clients, generating recurring revenue through its service business. Additionally, Motac holds an intellectual property portfolio of novel chemical entities and therapeutic targets, which it is developing through partnerships. The company's dual approach—offering CRO services while advancing its own pipeline—positions it to capitalize on the growing demand for CNS therapies, an area with high unmet need and significant clinical development challenges. With deep expertise in preclinical models and a lean operational model, Motac is well-placed to secure collaborations and progress its proprietary assets toward the clinic. While Motac operates in a competitive CRO landscape, its niche focus on CNS disorders, particularly Parkinson's, differentiates it from larger, generalized CROs. The company's early-stage pipeline represents upside potential but carries inherent preclinical risk. Over the coming year, key catalysts include new client partnerships, advancement of its lead compound into IND-enabling studies, and publication of preclinical efficacy data. These milestones could validate Motac's technology and drive value. However, as a private, pre-revenue company, visibility into specific timelines is limited. Overall, Motac presents a balanced risk-reward profile for investors seeking exposure to CNS drug development.

Upcoming Catalysts (preview)

• Q3 2026New pharma partnership for CRO services or co-development65% success
• Q1 2027Advancement of lead compound into IND-enabling studies40% success
• Q4 2026Publication of preclinical efficacy data in peer-reviewed journal70% success